Maynard Um
-
-
-
-
-
-
-
Compass Therapeutics (CMPX) PT Lowered to $6 at Stifel
-
-
-
-
-
-
-
Increasing unusual option volume: CMPX ALLO GSAT CTRA CORN IDYA
-
-
-
-
-
-
-
Raymond James Reiterates Outperform Rating on Compass Therapeutics (CMPX) following Q4 results
-
-
-
-
-
-
-
Compass Therapeutics names new commercial and medical officers
-
-
-
-
-
-
-
Compass Therapeutics presents preclinical data for cancer bispecific antibody
-
-
-
-
-
-
-
Raymond James Resumes Compass Therapeutics (CMPX) at Outperform
-
-
-
-
-
-
-
Compass Therapeutics (CMPX) to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
-
418,483 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

